NEXIUM 40 MG 84 TAB

$ 104.00

Gastro-resistant tablets.
* Therapeutic indications: Nexium tablets are indicated for:
& & # Gastroesophageal Reflux Disease (GERD):
& & – treatment of erosive reflux esophagitis.
& & – long-term management of patients with healed oesophagitis to prevent relapse.
& & – symptomatic treatment of gastro-oesophageal reflux disease (GORD).
& & # In combination with appropriate antibacterial therapeutic regimen for the eradication of
& & Helicobacter pylori and
& & – healing of duodenal ulcer associated with Helicobacter pylori and
& & – prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers.
& & # Patients requiring continued NSAID therapy:
& & – healing of gastric ulcers associated with NSAID therapy.
& & – prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk.
* CONTRAINDICATIONS:
& & – Known hypersensitivity to esomeprazole, substituted benzimidazoles or any other constituents
& & of the formulation.
& & – Esomeprazole like other PPIs should not be administered with atazanavir.
* Special warnings and special precautions for use:
& & – In the presence of any alarm symptom (eg. significant unintentional weight loss, recurrent vomiting,
& & dysphagia, haematemesis or melaena) and when gastric ulcer is suspected or present, malignancy
& & should be excluded, as treatment with Nexium may alleviate symptoms and delay diagnosis.
& & – Patients on long-term treatment (particularly those treated for more than a year) should be kept under
& & regular surveillance.
& & – Patients on on-demand treatment should be instructed to contact their physician if their symptoms change
& & in character. When prescribing esomeprazole for on demand therapy, the implications for interactions
& & with other pharmaceuticals, due to fluctuating plasma concentrations of esomeprazole should be considered.
& & – When prescribing esomeprazole for eradication of Helicobacter pylori possible drug interactions for all
& & components in the triple therapy should be considered. Clarithromycin is a potent inhibitor of CYP3A4
& & is used in patients concurrently taking other drugs metabolised via CYP3A4 such as cisapride.
& & – This medicinal product contains sucrose. Patients with rare hereditary problems of fructose intolerance,
& & glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
* Pregnancy and lactation:
& & – For Nexium, limited clinical data on exposed pregnancies are insufficient. Caution should be exercised
& & when prescribing to pregnant women.
& & – It is not known whether esomeprazole is excreted in human breast milk. No studies in lactating women
& & have been performed. Therefore NEXIUM should not be used during breast-feeding.
* Effects on ability to drive and use machines:
& & No effects have been observed.
* Posology and method of administration:
& & – The tablets should be swallowed whole with liquid. The tablets should not be chewed or crushed.
& & – For patients who have difficulty in swallowing, the tablets can also be dispersed in half a glass of
& & non-carbonated water. No other liquids should be used as the enteric coating may be dissolved.
& & Stir until the tablets disintegrate and drink the liquid with the pellets immediately or within 30 minutes.
& & Rinse the glass with half a glass of water and drink. The pellets must not be chewed or crushed.
& & – For patients who cannot swallow, the tablets can be dispersed in non-carbonated water and administered
& & through a gastric tube. It is important that the appropriateness of the selected syringe and tube is
& & carefully tested.
& & # Gastro-Oesophageal Reflux Disease (GORD):
& & . Treatment of erosive reflux oesophagitis: 40 mg once daily for four weeks.
& & An additional 4 weeks treatment is recommended for patients in whom oesophagitis has not healed or
& & who have persistent symptoms.
& & . Long-term management of patients with healed oesophagitis to prevent relapse: 20 mg once daily.
& & . Symptomatic treatment of gastro-oesophageal reflux disease (GORD): 20 mg once daily in patients
& & without esophagitis. If symptom control has not been achieved after four weeks, the patient should
& & be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved
& & using an on demand regimen taking 20 mg once daily, when needed. In NSAID treated patients at risk
& & of developing gastric and duodenal ulcers, subsequent symptom control using an on demand regimen
& & is not recommended.
& & # In combination with appropriate antibacterial therapeutic regimen for the eradication of Helicobacter pylori and
& & – healing of duodenal ulcer associated with Helicobacter pylori and
& & – prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers.
& & 20 mg NEXIUM with 1 g amoxicillin and 500 mg clarithromycin, all twice daily for 7 days.
& & # Patients requiring continued NSAID therapy:
& & – Healing of gastric ulcers associated with NSAID therapy: The usual dose is 20 mg once daily for 4 to 8 weeks.
& & – Prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk: 20 mg once daily.
& & # Children and Adolescents 12-18 years. Nexium should not be used in children since no data is available.
& & # Impaired renal function: Dosage adjustment is not required in patients with impaired renal function.
& & Due to limited experience in patients with severe renal insufficiency, such patients should be
& & treated with caution.
& & # Impaired hepatic function: Dose adjustment is not required in patients with mild to moderate liver impairment.
& & For patients with severe liver impairment, a maximum dose of 20 mg NEXIUM should not be exceeded.
& & # Elderly: Dose adjustment is not required in the eldery

Description

Gastro-resistant tablets.
* Therapeutic indications: Nexium tablets are indicated for:
& & # Gastroesophageal Reflux Disease (GERD):
& & – treatment of erosive reflux esophagitis.
& & – long-term management of patients with healed oesophagitis to prevent relapse.
& & – symptomatic treatment of gastro-oesophageal reflux disease (GORD).
& & # In combination with appropriate antibacterial therapeutic regimen for the eradication of
& & Helicobacter pylori and
& & – healing of duodenal ulcer associated with Helicobacter pylori and
& & – prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers.
& & # Patients requiring continued NSAID therapy:
& & – healing of gastric ulcers associated with NSAID therapy.
& & – prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk.
* CONTRAINDICATIONS:
& & – Known hypersensitivity to esomeprazole, substituted benzimidazoles or any other constituents
& & of the formulation.
& & – Esomeprazole like other PPIs should not be administered with atazanavir.
* Special warnings and special precautions for use:
& & – In the presence of any alarm symptom (eg. significant unintentional weight loss, recurrent vomiting,
& & dysphagia, haematemesis or melaena) and when gastric ulcer is suspected or present, malignancy
& & should be excluded, as treatment with Nexium may alleviate symptoms and delay diagnosis.
& & – Patients on long-term treatment (particularly those treated for more than a year) should be kept under
& & regular surveillance.
& & – Patients on on-demand treatment should be instructed to contact their physician if their symptoms change
& & in character. When prescribing esomeprazole for on demand therapy, the implications for interactions
& & with other pharmaceuticals, due to fluctuating plasma concentrations of esomeprazole should be considered.
& & – When prescribing esomeprazole for eradication of Helicobacter pylori possible drug interactions for all
& & components in the triple therapy should be considered. Clarithromycin is a potent inhibitor of CYP3A4
& & is used in patients concurrently taking other drugs metabolised via CYP3A4 such as cisapride.
& & – This medicinal product contains sucrose. Patients with rare hereditary problems of fructose intolerance,
& & glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
* Pregnancy and lactation:
& & – For Nexium, limited clinical data on exposed pregnancies are insufficient. Caution should be exercised
& & when prescribing to pregnant women.
& & – It is not known whether esomeprazole is excreted in human breast milk. No studies in lactating women
& & have been performed. Therefore NEXIUM should not be used during breast-feeding.
* Effects on ability to drive and use machines:
& & No effects have been observed.
* Posology and method of administration:
& & – The tablets should be swallowed whole with liquid. The tablets should not be chewed or crushed.
& & – For patients who have difficulty in swallowing, the tablets can also be dispersed in half a glass of
& & non-carbonated water. No other liquids should be used as the enteric coating may be dissolved.
& & Stir until the tablets disintegrate and drink the liquid with the pellets immediately or within 30 minutes.
& & Rinse the glass with half a glass of water and drink. The pellets must not be chewed or crushed.
& & – For patients who cannot swallow, the tablets can be dispersed in non-carbonated water and administered
& & through a gastric tube. It is important that the appropriateness of the selected syringe and tube is
& & carefully tested.
& & # Gastro-Oesophageal Reflux Disease (GORD):
& & . Treatment of erosive reflux oesophagitis: 40 mg once daily for four weeks.
& & An additional 4 weeks treatment is recommended for patients in whom oesophagitis has not healed or
& & who have persistent symptoms.
& & . Long-term management of patients with healed oesophagitis to prevent relapse: 20 mg once daily.
& & . Symptomatic treatment of gastro-oesophageal reflux disease (GORD): 20 mg once daily in patients
& & without esophagitis. If symptom control has not been achieved after four weeks, the patient should
& & be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved
& & using an on demand regimen taking 20 mg once daily, when needed. In NSAID treated patients at risk
& & of developing gastric and duodenal ulcers, subsequent symptom control using an on demand regimen
& & is not recommended.
& & # In combination with appropriate antibacterial therapeutic regimen for the eradication of Helicobacter pylori and
& & – healing of duodenal ulcer associated with Helicobacter pylori and
& & – prevention of relapse of peptic ulcers in patients with Helicobacter pylori associated ulcers.
& & 20 mg NEXIUM with 1 g amoxicillin and 500 mg clarithromycin, all twice daily for 7 days.
& & # Patients requiring continued NSAID therapy:
& & – Healing of gastric ulcers associated with NSAID therapy: The usual dose is 20 mg once daily for 4 to 8 weeks.
& & – Prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk: 20 mg once daily.
& & # Children and Adolescents 12-18 years. Nexium should not be used in children since no data is available.
& & # Impaired renal function: Dosage adjustment is not required in patients with impaired renal function.
& & Due to limited experience in patients with severe renal insufficiency, such patients should be
& & treated with caution.
& & # Impaired hepatic function: Dose adjustment is not required in patients with mild to moderate liver impairment.
& & For patients with severe liver impairment, a maximum dose of 20 mg NEXIUM should not be exceeded.
& & # Elderly: Dose adjustment is not required in the eldery

Reviews

There are no reviews yet.

Be the first to review “NEXIUM 40 MG 84 TAB”

Your email address will not be published. Required fields are marked *